세계의 요로상피암 치료제 시장 리포트(2023년)

“Urothelial Cancer Drugs Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urothelial cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urothelial cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The urothelial cancer drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Urothelial Carcinoma; Squamous Cell Carcinoma; Adenocarcinoma

• 2) By Treatment: Immunotherapy; Chemotherapy; Preservation Therapy

• 3) By Distribution Channel: Hospital Pharmacies; Specialty Clinics; Cancer Institutes; Ambulatory Surgical Centers

• Companies Mentioned: F Hoffmann La Roche AG; The Bristol-Myers Squibb Company; Merck & Co Inc; Pfizer Inc; Genentech Inc

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the urothelial cancer drugs market are: F Hoffmann La Roche AG, The Bristol-Myers Squibb Company, Merck & Co Inc., Pfizer Inc., Genentech Inc., GSK PLC., UroGen Pharma Inc., Johnson & Johnson, Astellas Pharma Inc., Sesen Bio Inc., Gilead Sciences Inc., Seagen Inc., Eisai Co Ltd., Agensys Inc.

The global urothelial cancer drugs market is expected to grow from $1.91 billion in 2023 to $2.33 billion in 2023 at a compound annual growth rate (CAGR) of 21.98%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The urothelial cancer drugs market is expected to reach $4.80 billion in 2027 at a CAGR of 19.81%.

The urothelial cancer drugs market consist of sales of targeted therapy urothelial cancer drugs and chemo therapy urothelial cancer drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Urothelial cancer drugs refer to medicines and therapies that treat cancer associated with urothelial cells that line the urethra, bladder, ureters, and renal pelvis. These are used to kill tumour cells and provide non-vesical chemotherapy. The urothelial cancer drug is used to prevent and treat urothelial cancer.

North America was the largest region in the urothelial cancer drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urothelial cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of urothelial cancer drugs are urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. The urothelial carcinoma is used to treat epithelial tissue tumors. Urothelial carcinoma refers to transitional cell cancer that occurs near epithelial tissues. The urothelial cancer drugs are used to treat immunotherapy, chemotherapy, and preservation therapy. The urothelial cancer drugs are distributed by hospital pharmacies, specialty clinics, cancer institutes, and ambulatory surgical centers.

The rising prevalence of urothelial cancer is expected to propel the urothelial cancer drug market going forward. Urothelial cancer is associated with urothelial cells that line the urethra, bladder, ureters, renal pelvis, and some other organs. The rising prevalence of urothelial cancer requires novel urothelial cancer drugs and therapies for treatment to reduce fatalities. For instance, in February 2022, according to the American Society of Clinical Oncology, a US-based professional organization, the total number of people diagnosed with bladder cancer was 573,278 and 212,536 people died from bladder cancer in 2020 across the globe. Thus, the rising prevalence of urothelial cancer will drive the urothelial cancer drug market.

Novel combination therapies are the key trends gaining popularity in the urothelial cancer drug market. Combination therapy combines two or more therapeutic agents for the treatment. Major players are concentrating on creating combination therapies to sustain their position in the urothelial cancer drug market. Combining immunotherapy with targeted drugs is an appealing treatment to reduce the emergence of resistance and improve response in cancer management. For instance, in July 2022, the United States Food and Drug Administration, a US-based federal agency of the Department of Health and Human Services, accepted the biologics license application (BLA) for an IL-15 superagonist, ImmunityBio's N-803 in combination with Bacillus Calmette-Guerin (BCG) vaccine for bladder cancer. N-803 in combination with BCG would be the first immunotherapy combination that can be delivered directly to induce natural killer cells and T cells in the bladder.

Rising prevalence of the geriatric population is driving the urothelial cancer drugs market. Adults 65 and older are referred to as members of the geriatric population. Due to lowered immunity and advanced age, the elderly population is susceptible to many diseases. The risk of urothelial cancer rises with age, due to which urothelial cancer drugs are required to treat them. For instance, according to the September 2020 report of the UN Department of Economic and Social Affairs, the population over the age of 65 is expected to increase from 9.3% in 2020 to almost 16.0% in 2050. Therefore, the rising prevalence of the geriatric population will propel the urothelial cancer drug market.

The countries covered in the Urothelial Cancer Drugs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The urothelial cancer drugs market research report is one of a series of new reports from The Business Research Company that provides urothelial cancer drugs market statistics, including urothelial cancer drugs industry global market size, regional shares, competitors with a urothelial cancer drugs market share, detailed urothelial cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the urothelial cancer drugs industry. This urothelial cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Urothelial Cancer Drugs Market Characteristics

3. Urothelial Cancer Drugs Market Trends And Strategies

4. Urothelial Cancer Drugs Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Urothelial Cancer Drugs Market
• 4.2. Ukraine-Russia War Impact On Urothelial Cancer Drugs Market
• 4.3. Impact Of High Inflation On Urothelial Cancer Drugs Market

5. Urothelial Cancer Drugs Market Size And Growth

• 5.1. Global Urothelial Cancer Drugs Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Urothelial Cancer Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Urothelial Cancer Drugs Market Segmentation

• 6.1. Global Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Urothelial Carcinoma
• Squamous Cell Carcinoma
• Adenocarcinoma
• 6.2. Global Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Immunotherapy
• Chemotherapy
• Preservation Therapy
• 6.3. Global Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospital Pharmacies
• Specialty Clinics
• Cancer Institutes
• Ambulatory Surgical Centers

7. Urothelial Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Urothelial Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Urothelial Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Urothelial Cancer Drugs Market

• 8.1. Asia-Pacific Urothelial Cancer Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Urothelial Cancer Drugs Market

• 9.1. China Urothelial Cancer Drugs Market Overview
• 9.2. China Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Urothelial Cancer Drugs Market

• 10.1. India Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Urothelial Cancer Drugs Market

• 11.1. Japan Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Urothelial Cancer Drugs Market

• 12.1. Australia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Urothelial Cancer Drugs Market

• 13.1. Indonesia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Urothelial Cancer Drugs Market

• 14.1. South Korea Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Urothelial Cancer Drugs Market

• 15.1. Western Europe Urothelial Cancer Drugs Market Overview
• 15.2. Western Europe Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Urothelial Cancer Drugs Market

• 16.1. UK Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Urothelial Cancer Drugs Market

• 17.1. Germany Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Urothelial Cancer Drugs Market

• 18.1. France Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Urothelial Cancer Drugs Market

• 19.1. Eastern Europe Urothelial Cancer Drugs Market Overview
• 19.2. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Urothelial Cancer Drugs Market

• 20.1. Russia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Urothelial Cancer Drugs Market

• 21.1. North America Urothelial Cancer Drugs Market Overview
• 21.2. North America Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Urothelial Cancer Drugs Market

• 22.1. USA Urothelial Cancer Drugs Market Overview
• 22.2. USA Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Urothelial Cancer Drugs Market

• 23.1. South America Urothelial Cancer Drugs Market Overview
• 23.2. South America Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Urothelial Cancer Drugs Market

• 24.1. Brazil Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Urothelial Cancer Drugs Market

• 25.1. Middle East Urothelial Cancer Drugs Market Overview
• 25.2. Middle East Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Urothelial Cancer Drugs Market

• 26.1. Africa Urothelial Cancer Drugs Market Overview
• 26.2. Africa Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Urothelial Cancer Drugs Market Competitive Landscape And Company Profiles

• 27.1. Urothelial Cancer Drugs Market Competitive Landscape
• 27.2. Urothelial Cancer Drugs Market Company Profiles
  • 27.2.1. F Hoffmann La Roche AG
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. The Bristol-Myers Squibb Company
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Merck & Co Inc
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Pfizer Inc
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Genentech Inc
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Urothelial Cancer Drugs Market

29. Urothelial Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer